The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Open accessAbstract
BACKGROUNDWhether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODSWe enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial.Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total.HIV-1 testing was performed every 4 weeks.The VRC01 80% inhibitory concentration (IC 80 ) of acquired isolates was measured with the TZM-bl assay. RESULTSAdverse events were similar in number and severity among the treatment groups within each trial.Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group.Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group.The incidence of HIV-1 infection per 100 person-years in HVTN 704/ HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70).In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC 80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9).The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONSVRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.(Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials .govnumbers, NCT02716675 and NCT02568215.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the broadly neutralizing mAbs, VRC01, have recently gained attention thanks to their ability to neutralize 98% of HIV strains167 and prevent transmission of antibody-sensitive strains with 75.4% efficacy168.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z., Li, Y., Högerkorp, C., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,724
Self-citationBroad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B. M., Diskin, R., Klein, F., Oliveira, T. Y., Pietzsch, J., Fenyö, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,161
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I. S., Wu, X., Yang, Z., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,123
Self-citationSeaman, M. S., Janes, H., Hawkins, N. R., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R., Harris, L. J., Wood, B., Daniels, M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02108-09 · Cited by 626
Self-citationEfficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 618
Self-citationMeasuring HIV Neutralization in a Luciferase Reporter Gene Assay
Montefiori, D. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-170-3_26 · Cited by 585
Self-citationCombination therapy with anti-HIV-1 antibodies maintains viral suppression
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K. G., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0531-2 · Cited by 560
Sarzotti‐Kelsoe, M., Bailer, R. T., Turk, E., Lin, C.-L., Bilska, M., Greene, K., Gao, H., Todd, C. A., Ozaki, D. A., Seaman, M. S., et al. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.11.022 · Cited by 535
Self-citationEffect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 466
Self-citation
Research works printed but not linked: 2
- 10.1128/JVI.00991-17 · DOI
- Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review. J Infect Dis 2020 June 30 (Epub ahead of print).32604408
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Delany‐Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J. M., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 609
Self-citationTackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 386
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K. J., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G. H., Hahn, B. H., Alt, F. W., et al. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00753-w · Cited by 375
Vaccination induces HIV broadly neutralizing antibody precursors in humans
Leggat, D. J., Cohen, K. W., Willis, J. R., Fulp, W. J., deCamp, A. C., Kalyuzhniy, O., Cottrell, C. A., Menis, S., Finak, G., Ballweber-Fleming, L., et al. (2022) · Science · doi:10.1126/science.add6502 · Cited by 293
Self-citationBekker, L., Beyrer, C., Mgodi, N. M., Lewin, S. R., Delany‐Moretlwe, S., Taiwo, B., Masters, M. C., & Lazarus, J. V. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00452-3 · Cited by 289
Self-citationUpdate and latest advances in antiretroviral therapy
Menéndez‐Arias, L., & Delgado, R. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.004 · Cited by 229
Prolonged viral suppression with anti-HIV-1 antibody therapy
Gaebler, C., Nogueira, L., Stoffel, E., Oliveira, T. Y., Breton, G., Millard, K. G., Turroja, M., Butler, A. L., Ramos, V., Seaman, M. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04597-1 · Cited by 204
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 168
Prevention, treatment and cure of HIV infection
Landovitz, R. J., Scott, H. M., & Deeks, S. G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00914-1 · Cited by 153
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Mody, A., Sohn, A. H., Iwuji, C. C., Tan, R. K. J., Venter, F., & Geng, E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01381-8 · Cited by 150
Jülg, B. D., Stephenson, K. E., Wagh, K., Tan, S. C., Zash, R., Walsh, S. R., Ansel, J. L., Kanjilal, D. G., Nkolola, J. P., Walker-Sperling, V. E. K., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01815-1 · Cited by 132
Self-citationNeutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Gilbert, P. B., Huang, Y., deCamp, A. C., Karuna, S., Zhang, Y., Magaret, C. A., Giorgi, E. E., Korber, B., Edlefsen, P. T., Rossenkhan, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01953-6 · Cited by 122
Self-citationA General Framework for Inference on Algorithm-Agnostic Variable Importance
Williamson, B. D., Gilbert, P. B., Simon, N., & Carone, M. (2021) · Journal of the American Statistical Association · doi:10.1080/01621459.2021.2003200 · Cited by 107
Self-citationCurrent approaches to HIV vaccine development: a narrative review
Kim, J., Vasan, S., Kim, J. H., & Ake, J. A. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25793 · Cited by 88
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“Corey and co-authors have recently shown in two trials that administration of VRC01 did not prevent HIV-1 infection (Corey et al., 2021).”
Broadly Neutralizing Antibodies for HIV-1 Prevention
Walsh, S. R., & Seaman, M. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712122 · Cited by 77
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Willis, J. R., Prabhakaran, M. S., Muthui, M. K., Naidoo, A., Sincomb, T., Wu, W., Cottrell, C. A., Landais, E., deCamp, A. C., Keshavarzi, N., et al. (2025) · Science · doi:10.1126/science.adr8382 · Cited by 77
Self-citationWillis, J. R., Berndsen, Z. T., Krystal, M., Steichen, J. M., Schiffner, T., Landais, E., Liguori, A., Kalyuzhniy, O., Allen, J. D., Baboo, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.001 · Cited by 76
Cohen, K. W., Rosa, S. C. D., Fulp, W. J., deCamp, A. C., Fiore-Gartland, A. J., Mahoney, C. R., Furth, S., Donahue, J. G., Whaley, R. E., Ballweber-Fleming, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf3309 · Cited by 80
Self-citationImproved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
Dangi, T., Sanchez, S., Class, J., Richner, M., Visvabharathy, L., Chung, Y. R., Bentley, K., Stanton, R. J., Koralnik, I. J., Richner, J. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162282 · Cited by 69
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Williams, W. B., Alam, S. M., Ofek, G., Erdmann, N. B., Montefiori, D. C., Seaman, M. S., Wagh, K., Korber, B., Edwards, R. J., Mansouri, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.033 · Cited by 68
Self-citationJülg, B. D., Walker-Sperling, V. E. K., Wagh, K., Aïd, M., Stephenson, K. E., Zash, R., Liu, J., Nkolola, J. P., Hoyt, A., Castro, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03247-5 · Cited by 68
Cottrell, C. A., Hu, X., Lee, J. H., Skog, P. D., Luo, S., Flynn, C. T., McKenney, K. R., Hurtado, J., Kalyuzhniy, O., Liguori, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0223 · Cited by 67
Self-citationVaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques
Saunders, K. O., Counts, J. A., Thakur, B., Stalls, V., Edwards, R. J., Manne, K., Lu, X., Mansouri, K., Chen, Y., Parks, R., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.002 · Cited by 68
Self-citationProphylactic HIV-1 vaccine trials: past, present, and future
Nkolola, J. P., & Barouch, D. H. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00264-3 · Cited by 61
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
Caniels, T. G., Medina-Ramírez, M., Zhang, J., Sarkar, A., Kumar, S., LaBranche, A., Derking, R., Allen, J. D., Snitselaar, J. L., Capella-Pujol, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101003 · Cited by 61
Self-citationPrecise targeting of HIV broadly neutralizing antibody precursors in humans
Caniels, T. G., Prabhakaran, M. S., Ozorowski, G., MacPhee, K. J., Wu, W., van der Straten, K., Agrawal, S., Derking, R., Reiss, E. I. M. M., Millard, K. G., et al. (2025) · Science · doi:10.1126/science.adv5572 · Cited by 56
Self-citationHIV prevention: better choice for better coverage
Bekker, L., Pike, C., & Hillier, S. L. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25872 · Cited by 55
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Mkhize, N. N., Yssel, A., Kaldine, H., van Dorsten, R. T., Davis, A. S. W., Beaume, N., Matten, D., Lambson, B. E., Modise, T., Kgagudi, P., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011469 · Cited by 53
Self-citationMcFarland, E. J., Cunningham, C. K., Muresan, P., Capparelli, E. V., Perlowski, C., Morgan, P., Smith, B., Hazra, R., Purdue, L., Harding, P. A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab229 · Cited by 54
Self-citationLi, H., Wang, S., Lee, F.-H., Roark, R. S., Murphy, A. I., Smith, J., Zhao, C., Rando, J. M., Chohan, N., Ding, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00071-21 · Cited by 50
Eron, J. J., Little, S. J., Crofoot, G. E., Cook, P., Ruane, P. J., Jayaweera, D. T., VanderVeen, L. A., DeJesus, E., Zheng, Y., Mills, A., et al. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(23)00293-x · Cited by 50
Shapiro, R., Ajibola, G., Maswabi, K., Hughes, M. D., Nelson, B. S., Niesar, A., Holme, M. P., Powis, K. M., Sakoi, M., Batlang, O., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0004 · Cited by 49
Self-citationRecent advances in poor HIV immune reconstitution: what will the future look like?
Zhang, W., & Ruan, L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1236460 · Cited by 52
Kana, B. D., Arbuthnot, P. B., Botwe, B. K., Choonara, Y. E., Hassan, F., Louzir, H., Matsoso, P., Moore, P. L., Muhairwe, A., Naidoo, K., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00878-7 · Cited by 48
Bringing immunofocusing into focus
Musunuri, S., Weidenbacher, P. A. B., & Kim, P. S. (2024) · npj Vaccines · doi:10.1038/s41541-023-00792-x · Cited by 48
Chaudhary, N., Newby, A. N., Arral, M. L., Yerneni, S. S., LoPresti, S. T., Doerfler, R., Petersen, D. M. S., Montoya, C., Kim, J. S., Fox, B., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307810121 · Cited by 49
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site
Caniels, T. G., Medina-Ramírez, M., Zhang, S., Kratochvil, S., Xian, Y., Koo, J., Derking, R., Samsel, J., van Schooten, J., Pecetta, S., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adk9550 · Cited by 53
Self-citationProgramming cytomegalovirus as an HIV vaccine
Picker, L. J., Lifson, J. D., Gale, M., Hansen, S. G., & Früh, K. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.02.001 · Cited by 46
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
Spencer, D. A., Shapiro, M. B., Haigwood, N. L., & Hessell, A. J. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.690017 · Cited by 52
HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies
Kreider, E. F., & Bar, K. J. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-022-00604-2 · Cited by 46
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44
Self-citationHuman immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
deCamp, A. C., Corcoran, M., Fulp, W. J., Willis, J. R., Cottrell, C. A., Bader, D. L., Kalyuzhniy, O., Leggat, D. J., Cohen, K. W., Hyrien, O., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00811-5 · Cited by 43
Self-citationThe Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Thavarajah, J. J., Hønge, B. L., & Wejse, C. M. (2024) · Viruses · doi:10.3390/v16060911 · Cited by 47
Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review
Derking, R., & Sanders, R. W. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25797 · Cited by 46
Broadly neutralizing monoclonal antibodies for HIV prevention
Miner, M. D., Corey, L., & Montefiori, D. C. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25829 · Cited by 43
Self-citationAdvancing the prevention and treatment of HIV in children: priorities for research and development
Penazzato, M., Townsend, C. L., Sam-Agudu, N. A., Ruel, T., Archary, M., Bekker, A., Cressey, T. R., Colbers, A. P. H., Sugandhi, N., Rojo, P., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00101-1 · Cited by 42
Current Status of HIV-1 Vaccines
Hargrave, A., Mustafa, A. S., Hanif, A., Tunio, J. H., & Hanif, S. N. M. (2021) · Vaccines · doi:10.3390/vaccines9091026 · Cited by 41
Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
Williams, W. B., Wiehe, K. J., Saunders, K. O., & Haynes, B. F. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25831 · Cited by 43
Hahn, W. O., Parks, K. R., Shen, M., Ozorowski, G., Janes, H., Ballweber-Fleming, L., Davis, A. S. W., Duplessis, C. A., Tomai, M. A., Dey, A., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240604 · Cited by 40
Self-citationCan Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu, D. C., Mellors, J. W., & Vasan, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710044 · Cited by 38
Sobieszczyk, M. E., Mannheimer, S., Paez, C. A., Yu, C., Gamble, T., Theodore, D., Chege, W., Yacovone, M. A., Hanscom, B. S., Heptinstall, J., et al. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00140-6 · Cited by 36
Self-citationBroadly neutralizing antibodies against HIV-1 and concepts for application
Gruell, H., & Schommers, P. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101211 · Cited by 36
Saunders, K. O., Edwards, R. J., Tilahun, K., Manne, K., Lu, X., Cain, D. W., Wiehe, K. J., Williams, W. B., Mansouri, K., Hernandez, G. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5598 · Cited by 36
Self-citationBhagchandani, S. H., Yang, L., Lam, J. H., Maiorino, L., Ben‐Akiva, E., Rodrigues, K. A., Romanov, A. M., Suh, H., Aung, A., Wu, S., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adl3755 · Cited by 34
Mahomed, S., Garrett, N., Capparelli, E. V., Osman, F., Harkoo, I., Yende‐Zuma, N., Gengiah, T. N., Archary, D., Samsunder, N., Baxter, C., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac041 · Cited by 34
Self-citationHow could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Parikh, U. M., & Mellors, J. W. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000746 · Cited by 34
Mahomed, S., Garrett, N., Capparelli, E. V., Osman, F., Mkhize, N. N., Harkoo, I., Gengiah, T. N., Mansoor, L. E., Baxter, C., Archary, D., et al. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00003-6 · Cited by 34
Self-citationBroadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Mahomed, S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00152-22 · Cited by 37
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Seaton, K. E., Huang, Y., Karuna, S., Heptinstall, J., Brackett, C., Chiong, K. T., Zhang, L., Yates, N. L., Sampson, M., Rudnicki, E., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104590 · Cited by 33
Self-citationWestfall, D. H., Deng, W., Pankow, A. P., Murrell, H., Chen, L., Zhao, H. C., Williamson, C. E., Rolland, M., Murrell, B., & Mullins, J. I. (2024) · Virus Evolution · doi:10.1093/ve/veae019 · Cited by 31
Self-citationIs HIV epidemic control by 2030 realistic?
Beyrer, C., Tomaras, G. D., Gelderblom, H. C., Gray, G. E., Janes, H., Bekker, L., Millett, G. A., Pantaleo, G., Buchbinder, S. P., & Corey, L. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(24)00098-5 · Cited by 31
Self-citationParthasarathy, D., Pothula, K. R., Dam, K.-M. A., Ratnapriya, S., Cervera, H., Parsons, R., Huang, X., Sammour, S., Janowska, K., Harris, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51656-4 · Cited by 31
Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review
Mahomed, S., Pillay, K., Hassan-Moosa, R., Galvão, B. P. G. V., Burgers, W. A., Moore, P. L., Rose-Abrahams, M., Williamson, C. E., & Garrett, N. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00734-8 · Cited by 37
Self-citationSpencer, D. A., Goldberg, B. S., Pandey, S., Cheever, T., Dufloo, J., Barnette, P. T., Sutton, W. F., Henderson, H., Agnor, R., Gao, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28250-7 · Cited by 30
The future of long-acting agents for preexposure prophylaxis
Flexner, C. W. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000735 · Cited by 30
Richardson, S. I., Ayres, F., Manamela, N. P., Oosthuysen, B., Makhado, Z., Lambson, B. E., Morris, L., & Moore, P. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733958 · Cited by 29
Self-citationPotent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys
Pegu, A., Xu, L., DeMouth, M. E., Fabozzi, G., March, K., Almasri, C. G., Cully, M. D., Wang, K., Yang, E. S., Dias, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110199 · Cited by 29
Self-citationAhmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 29
Peters, R. P. H., Grinsztejn, B. G. J., Celum, C., Mayer, K. H., Molina, J., Delany‐Moretlwe, S., Ngure, K., Rueda, S. T., Guy, R., Reiss, P., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00983-3 · Cited by 29
Gristick, H. B., Hartweger, H., Loewe, M., van Schooten, J., Ramos, V., Oliveira, T. Y., Nishimura, Y., Koranda, N. S., Wall, A., Yao, K.-H., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade6364 · Cited by 30
Mayer, B. T., Zhang, L., deCamp, A. C., Yu, C., Sato, A., Angier, H. E., Seaton, K. E., Yates, N. L., Ledgerwood, J. E., Mayer, K. H., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050594 · Cited by 27
Self-citationThe impact of sex on HIV immunopathogenesis and therapeutic interventions
Mihealsick, E., Word, A., & Scully, E. P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180075 · Cited by 27
Immune-mediated strategies to solving the HIV reservoir problem
Kulpa, D. A., Paiardini, M., & Silvestri, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01136-7 · Cited by 30
Future of bNAbs in HIV Treatment
Tebas, P. (2025) · Current HIV/AIDS Reports · doi:10.1007/s11904-025-00744-1 · Cited by 33
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
Mayer, B. T., deCamp, A. C., Huang, Y., Schiffer, J. T., Gottardo, R., Gilbert, P. B., & Reeves, D. B. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010003 · Cited by 26
Self-citationNovel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV
Ruel, T., Penazzato, M., Zech, J. M., Archary, M., Cressey, T. R., Goga, A. E., Harwell, J. I., Landovitz, R. J., Lain, M. G., Lallemant, M. J., et al. (2023) · Global Health Science and Practice · doi:10.9745/ghsp-d-22-00401 · Cited by 26
Reeves, D. B., Mayer, B. T., deCamp, A. C., Huang, Y., Zhang, B., Carpp, L. N., Magaret, C. A., Juraska, M., Gilbert, P. B., Montefiori, D. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43384-y · Cited by 25
Self-citationAstronomo, R. D., Lemos, M. P., Narpala, S., Czartoski, J., Ballweber-Fleming, L., Seaton, K. E., Prabhakaran, M. S., Huang, Y., Lu, Y., Westerberg, K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146975 · Cited by 25
Self-citationA naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Barnes, C. O., Schoofs, T., Gnanapragasam, P. N. P., Golijanin, J., Huey‐Tubman, K. E., Gruell, H., Schommers, P., Suh-Toma, N., Lee, Y. E., Lorenzi, J. C. C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8155 · Cited by 25
Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
Beesham, I., Milford, C., Smit, J. A., Davey, D. J., Baeten, J. M., Heffron, R. A., Beksinska, M. E., & Mansoor, L. E. (2023) · BMC Public Health · doi:10.1186/s12889-023-16139-z · Cited by 24
Juraska, M., Bai, H., deCamp, A. C., Magaret, C. A., Li, L., Gillespie, K., Carpp, L. N., Giorgi, E. E., Ludwig, J., Molitor, C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308942121 · Cited by 24
Self-citationProgress and Recent Developments in HIV Vaccine Research
Shim, I., Rogowski, L., & Venketaraman, V. (2025) · Vaccines · doi:10.3390/vaccines13070690 · Cited by 25
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
Awan, S. F., Happe, M., Hofstetter, A. R., & Gama, L. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000742 · Cited by 24
Steering and controlling evolution — from bioengineering to fighting pathogens
Lässig, M., Mustonen, V., & Nourmohammad, A. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00623-8 · Cited by 24
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
Chang, X., Webb, G. M., Wu, H. L., Greene, J., Abdulhaqq, S. A., Bateman, K. B., Reed, J. S., Pessoa, C. T., Weber, W. C., Maier, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23697-6 · Cited by 23
Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination
Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.015 · Cited by 23
Parkin, N. T., Gao, F., Grebe, E., Cutrell, A. G., Das, M., Donnell, D. J., Duerr, A. C., Glidden, D. V., Hughes, J. P., Murray, J. S., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2830 · Cited by 23
Self-citationPharmacological advances in HIV treatment: from ART to long-acting injectable therapies
Łupina, K., Nowak, K., Lorek, D., Nowak, A., Romac, A., Głowacka, E., & Janczura, J. (2025) · Archives of Virology · doi:10.1007/s00705-025-06381-8 · Cited by 25
Tipoe, T., Fidler, S. J., & Frater, J. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000731 · Cited by 23
Meeting Summary: Global Vaccine and Immunization Research Forum, 2021
Ford, A., Hwang, A., Mo, A. X. Y., Baqar, S., Touchette, N. A., Deal, C. D., King, D., Earle, K. A., Giersing, B. K., Dull, P. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.028 · Cited by 24
Haynes, B. F., Wiehe, K. J., Alam, S. M., Weissman, D., & Saunders, K. O. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000820 · Cited by 22
Kaur, A., & Vaccari, M. (2024) · Viruses · doi:10.3390/v16030368 · Cited by 22
Williamson, B. D., Magaret, C. A., Gilbert, P. B., Nizam, S., Simmons, C., & Benkeser, D. C. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab398 · Cited by 22
Self-citationKwon, Y. D., Asokan, M., Gorman, J., Zhang, B., Liu, Q., Louder, M. K., Lin, B. C., McKee, K., Pegu, A., Verardi, R., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1946918 · Cited by 22
Self-citationHIV Vaccine Development at a Crossroads: New B and T Cell Approaches
Govindan, R., & Stephenson, K. E. (2024) · Vaccines · doi:10.3390/vaccines12091043 · Cited by 20
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing
Walker, L. M., Shiakolas, A. R., Venkat, R., Liu, Z. A., Wall, S. C., Raju, N., Pilewski, K. A., Setliff, I., Murji, A. A., Gillespie, R. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.855772 · Cited by 21
Self-citation
Metadata
- Authors
- Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., Huang, Y., Gonzales, P., Cabello, R., Orrell, C., Lama, J. R., Laher, F., Lazarus, E. M., Sanchez, J., Frank, I., Hinojosa, J., Sobieszczyk, M. E., Marshall, K. E., Mukwekwerere, P. G., Makhema, J., Baden, L. R., Mullins, J. I., Williamson, C., Hural, J., McElrath, M. J., Bentley, C., Takuva, S., Gomez Lorenzo, M. M., Burns, D. N., Espy, N., Randhawa, A. K., Kochar, N., Piwowar-Manning, E., Donnell, D. J., Sista, N., Andrew, P., Kublin, J. G., Gray, G., Ledgerwood, J. E., Mascola, J. R., & Cohen, M. S.
- Affiliations
- University of the Witwatersrand (ZA)
- National Health Laboratory Service (ZA)
- Emory University (US)
- University of Zimbabwe (ZW)
- From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center (L.C., P.B.G., M.J., S.T.K., A.C.C., E.R., Y.H., K.E.M., J. Hural, M.J.M.E., C.B., S.T., N.E., A.K.R., N.K., D.J.D., J.G.K., G.G.), and the Departments of Global Health, Microbiology, and Medicine, University of Washington (J.I.M.), Seattle; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center (D.C.M.), and FHI 360 (N.S., P.A.), Durham, and the Institute for Global Health and Infectious Disease, University of North Carolina, Chapel Hill (M.S.C.) — both in North Carolina; the National Institute for Communicable Diseases of the National Health Laboratory Service (L.M.) and the Antibody Immunity Research Unit, Faculty of Health Sciences (L.M.), and the Perinatal HIV Research Unit, Faculty of Health Sciences (F.L., E.M.L., S.T.), University of the Witwatersrand, Johannesburg, the Desmond Tutu HIV Centre, Department of Medicine and Institute of Infectious Disease and Molecular Medicine ...
- Brigham and Women's Hospital (US)
- University of Cape Town (ZA)
- Family Health International 360 (US)
- South African Medical Research Council (ZA)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Corey, Lawrence
- Gilbert, Peter B.
- Juraska, Michal
- Montefiori, David C.
- Morris, Lynn
- Karuna, Shelly T.
- Edupuganti, Srilatha
- Mgodi, Nyaradzo M.
- deCamp, Allan C.
- Huang, Yunda
- Cabello, Robinson
- Orrell, Catherine
- Lama, Javier R.
- Laher, Fatima
- Lazarus, Erica M.
- Frank, Ian
- Sobieszczyk, Magdalena E.
- Marshall, Kyle E.
- Mukwekwerere, Pamela G.
- Makhema, Joseph
- Baden, Lindsey R.
- Mullins, James I.
- Williamson, Carolyn
- Hural, John
- McElrath, M. Juliana
- Takuva, Simbarashe
- Burns, David N.
- Espy, Nicole
- Randhawa, April K.
- Donnell, Deborah J.
- Andrew, Philip
- Kublin, James G.
- Gray, Glenda
- Ledgerwood, Julie E.
- Mascola, John R.
- Cohen, Myron S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-18
- Volume
- 384
- Issue
- 11
- Pages
- 1003-1014
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8189692
- OpenAlex
- W3138945586
- Cited by
- 538
- References
- 31
- Citations by year
- 2026: 87 · 2025: 108 · 2024: 98 · 2023: 98 · 2022: 78 · 2021: 66
- FWCI
- 47.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- IRIS (submittedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- UNC Libraries
- Funders
- National Institute of Allergy and Infectious Diseases (P30 AI027757, UM1 AI068614, UM1 AI068618, UM1 AI068619, UM1 AI068635, UM1AI068613, UM1AI068617)
- Intramural Research Program of the NIH, NIAID
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- HIV-1 prevention, broadly neutralizing antibodies, VRC01, HIV-1 acquisition, HIV-1 envelope glycoprotein, HIV-1 isolates
- MeSH terms
- Proof of Concept Study, Broadly Neutralizing Antibodies, Adolescent, Adult, Americas, Antibodies, Monoclonal, Double-Blind Method, Europe, Female, Humans, Male, HIV Antibodies, HIV-1, HIV Infections, Incidence, Africa South of the Sahara, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
